- Home
- LPTX vs DYAI Comparison
LPTX vs DYAI Comparison
Compare LPTX & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- DYAI
- Stock Information
- Founded
- LPTX 2011
- DYAI 1979
- Country
- LPTX United States
- DYAI United States
- Employees
- LPTX N/A
- DYAI N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPTX Health Care
- DYAI Health Care
- Exchange
- LPTX Nasdaq
- DYAI Nasdaq
- Market Cap
- LPTX 35.4M
- DYAI 30.2M
- IPO Year
- LPTX N/A
- DYAI 2004
- Fundamental
- Price
- LPTX $0.48
- DYAI $1.10
- Analyst Decision
- LPTX Hold
- DYAI Strong Buy
- Analyst Count
- LPTX 1
- DYAI 2
- Target Price
- LPTX N/A
- DYAI $4.50
- AVG Volume (30 Days)
- LPTX 7.7M
- DYAI 89.7K
- Earning Date
- LPTX 11-13-2025
- DYAI 11-12-2025
- Dividend Yield
- LPTX N/A
- DYAI N/A
- EPS Growth
- LPTX N/A
- DYAI N/A
- EPS
- LPTX N/A
- DYAI N/A
- Revenue
- LPTX N/A
- DYAI $4,135,078.00
- Revenue This Year
- LPTX N/A
- DYAI $34.23
- Revenue Next Year
- LPTX N/A
- DYAI $19.57
- P/E Ratio
- LPTX N/A
- DYAI N/A
- Revenue Growth
- LPTX N/A
- DYAI 129.20
- 52 Week Low
- LPTX $0.22
- DYAI $0.71
- 52 Week High
- LPTX $4.79
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- LPTX 47.84
- DYAI 49.67
- Support Level
- LPTX $0.43
- DYAI $1.10
- Resistance Level
- LPTX $0.56
- DYAI $1.29
- Average True Range (ATR)
- LPTX 0.06
- DYAI 0.11
- MACD
- LPTX -0.02
- DYAI -0.00
- Stochastic Oscillator
- LPTX 16.04
- DYAI 34.49
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.